Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population

Clin Chim Acta. 2011 Jan 14;412(1-2):139-42. doi: 10.1016/j.cca.2010.09.026. Epub 2010 Sep 29.

Abstract

Background: Asymmetric dimethylarginine (ADMA), a circulating endogenous inhibitor of nitric oxide synthase, has been associated with the pathogenesis of atherosclerosis. The present study was initiated to investigate the role of ADMA as a biomarker of risk for early-onset ischemic stroke.

Methods: Plasma ADMA levels were measured in 201 ischemic stroke patients aged between 15 and 50 years and 217, age and gender-matched healthy controls, by high performance liquid chromatography using pre-column derivatization with O-phthaldialdehyde.

Results: Patients with ischemic stroke had significantly higher plasma ADMA compared with the controls (1.49 vs. 0.97 μmol/l, p < 0.001). After adjustment for vascular risk factors, increased ADMA was associated with stroke (OR=1.55, 95% CI 1.25-1.92, p < 0.001). Univariate analysis showed that ADMA was significantly associated with age, alcohol, smoking, hypertension, diabetes mellitus, low serum HDL-cholesterol and homocysteine. By multiple stepwise linear regression analysis, diabetes, HDL-cholesterol and homocysteine were found to be independent determinants of plasma ADMA.

Conclusions: Increased plasma ADMA is associated with increased risk for ischemic stroke in the young. Diabetes mellitus, HDL-cholesterol and homocysteine are independent predictors of elevation in plasma ADMA concentration.

MeSH terms

  • Adolescent
  • Adult
  • Analysis of Variance
  • Arginine / analogs & derivatives*
  • Arginine / blood
  • Biomarkers / blood
  • Brain Ischemia / complications*
  • Case-Control Studies
  • Female
  • Humans
  • India
  • Linear Models
  • Male
  • Middle Aged
  • Risk
  • Stroke / blood*
  • Stroke / complications*
  • Time Factors
  • Young Adult

Substances

  • Biomarkers
  • N,N-dimethylarginine
  • Arginine